Healthcare Industry News: Allergan
News Release - March 18, 2011
Bausch + Lomb Appoints Dr. Calvin W. Roberts as Chief Medical OfficerNew Leadership Role Will Coordinate Global Development and Research Across Business Units for Optimal Outcomes
ROCHESTER, NY--(Healthcare Sales & Marketing Network) - Bausch + Lomb, the global eye health company, today announced the appointment of Calvin W. Roberts, M.D. to the newly created position of Chief Medical Officer (CMO). Dr. Roberts will serve as a member of the Executive Leadership Team and coordinate the company's global D&R efforts across the Vision Care, Pharmaceuticals and Surgical business units for greater leverage and outcomes.
Dr. Roberts brings a unique combination of academic, clinical and product development experience to the new Bausch + Lomb CMO role. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing and producing over-the-counter products for vision care, prescription ocular therapeutics and innovative treatment regimens. Dr. Roberts is considered to be the "father" of ophthalmic non-steroidals; he has published 50 peer-reviewed articles.
"We are extremely pleased with the addition of Dr. Calvin Roberts to the Bausch + Lomb leadership team in this critical new role as chief medical officer," said Brent Saunders, chief executive officer of Bausch + Lomb. "As a renowned expert in ophthalmology and the development of eye health products, Cal is uniquely qualified to help us further strengthen product innovation, benefiting our customers and their patients around the world."
Dr. Roberts is a member of the board of directors at Alimera Sciences, a biopharmaceutical company he co-founded in 2003. Dr. Roberts is a clinical professor of ophthalmology at Weill Medical College of Cornell University. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and is the developer of instruments for cataract surgery. As a consultant to ophthalmic pharmaceutical companies, including Allergan Pharmaceuticals, Johnson & Johnson and Novartis, Dr. Roberts has helped lead the development and marketing efforts for several new therapeutics.
A graduate of Princeton University and the College of Physicians and Surgeons of Columbia University, Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital in New York. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston.
"I look forward to bringing the perspective of clinical optometrists and ophthalmologists to the development of new, innovative products to benefit our patients," said Dr. Calvin Roberts. "Bausch + Lomb has a history of great science and great scientists, and working together we can best serve the needs of our customers and patients."
About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
Source: Bausch & Lomb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBausch & Lomb ULTRA(R) Multifocal for Astigmatism Contact Lenses Now Available in the United States
Bausch & Lomb Announces the U.S. Launch of LOTEMAX(R) SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% for the Treatment of Postoperative Inflammation and Pain Following Ocular Surgery
Bausch & Lomb Receives 510(k) Clearance For Use Of The Tangible(R) Hydra-PEG(R) Custom Contact Lens Coating Technology On Several Of Its Boston(R) Gas Permeable Lens Materials And Zenlens(TM) Family Of Scleral Lenses